Antibody pipeline

MediaPharma is committed to developing innovative products based on monoclonal antibodies designed to safely and effectively treat patients with cancer and improve patient outcomes.

[...] Read More

Personalized medicine

At the present, one of the major problems in cancer treatment lies in the lack of suitable assays to select patients more likely to respond to a given anticancer therapy.

[...] Read More

Partnering

MediaPharma intends to advance its proprietary products portfolio to initial clinical safety and efficacy endpoints, then form strategic partnerships with companies that have the necessary commercialization infrastructures to best capture value.

[...] Read More

Antibody pipeline Personalized medicine Partnering

Ultime News

Antibody pipeline

MP-EV20-RT

EV20 labeled with ⁸⁹Zr

Preclinical proof of activity established: in vivo localization of HER3+ human tumor xenografts.

Indications in Oncology
In vivo localization of HER3-expressing cancer by immuno-PET.

Pubblicato in Products

I commenti sono chiusi.

Antibody pipeline

Personalized medicine

Partnering

Highlights

Ultime News

MP-EV20-RT

EV20 labeled with ⁸⁹Zr

Company

R&D

Careers

Business

Antibody pipeline

Personalized medicine

Partnering

Highlights

Ultime News

MP-EV20-RT

EV20 labeled with 89Zr

Company

R&D

Careers

Business

EV20 labeled with ⁸⁹Zr